We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alte... CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California. Show more
Ask ADVFN Intelligence (AI)
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.03 | 0.655021834061 | 4.58 | 4.65 | 4.56 | 2358731 | 4.59738521 | CS |
| 4 | 0.23 | 5.25114155251 | 4.38 | 4.75 | 4.0712 | 2275299 | 4.54866053 | CS |
| 12 | -0.09 | -1.91489361702 | 4.7 | 4.77 | 3.775 | 1147370 | 4.46534734 | CS |
| 26 | -7.51 | -61.9636963696 | 12.12 | 14.6785 | 3 | 1173269 | 4.51813988 | CS |
| 52 | -13.22 | -74.1446999439 | 17.83 | 25.45 | 3 | 715982 | 7.21629156 | CS |
| 156 | -10.84 | -70.1618122977 | 15.45 | 33.92 | 3 | 523661 | 9.868716 | CS |
| 260 | -10.84 | -70.1618122977 | 15.45 | 33.92 | 3 | 523661 | 9.868716 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
